South Delhi Pharma, New Delhi, India
VOTRIENT (pazopanib) tablets.
Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call 9891296838 or Email query@southdelhipharma.com to discuss.
VOTRIENT is a prescription medicine. VORAXAZE is used for kidney cancer and cancer (soft tissue sarcoma) treatment.
INDICATIONS AND USAGE
VOTRIENT is a kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma.
DOSAGE FORMS & STRENGTHS
200 mg and 400 mg tablets.
Manufactured By: GlaxoSmithKline
Prescribing Information URL: Click Here
South Delhi Pharma can facilitate the supply of “VOTRIENT (pazopanib) tablets” to all locations in India and other part of countries after fulfilling the legal requirement (if applicable). All Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from South Delhi Pharma.
Get In Touch
Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.
The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.
Contact Number:
M:+91-9891296838 / P:+91-11- 26532129
Email ID:
info@southdelhipharma.com
Pazopanib, sold under the brand name Votrient, is an anti-cancer medication. It is a potent and selective multi-targeted receptor tyrosine kinase inhibitor that blocks tumour growth and inhibits angiogenesis. It has been approved for renal cell carcinoma and soft tissue sarcoma by numerous regulatory administrations worldwide.
It is approved by numerous regulatory administrations worldwide, including the US Food and Drug Administration (FDA) (19 October 2009), the European Union's European Medicines Agency (EMA) (14 June 2010), the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) (14 June 2010) and Australia's Therapeutic Goods Administration (TGA) (30 June 2010), for use as a treatment for advanced/metastatic renal cell carcinoma and advanced soft tissue sarcomas.
